Sign in or Register   Sign in or Register
  |  

Mouse Anti-IDE Recombinant Antibody (A372) (CBMAB-AP3550LY)

The product is antibody recognizes IDE. The antibody A372 immunoassay techniques such as: ELISA, WB.
See all IDE antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
A372
Antibody Isotype
IgG
Application
ELISA, WB

Basic Information

Immunogen
Synthetic Peptide
Specificity
Human
Antibody Isotype
IgG
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Purity
Affinity purity
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name
Insulin Degrading Enzyme
Introduction
This gene encodes a zinc metallopeptidase that degrades intracellular insulin, and thereby terminates insulins activity, as well as participating in intercellular peptide signalling by degrading diverse peptides such as glucagon, amylin, bradykinin, and kallidin. The preferential affinity of this enzyme for insulin results in insulin-mediated inhibition of the degradation of other peptides such as beta-amyloid. Deficiencies in this protein's function are associated with Alzheimer's disease and type 2 diabetes mellitus but mutations in this gene have not been shown to be causitive for these diseases. This protein localizes primarily to the cytoplasm but in some cell types localizes to the extracellular space, cell membrane, peroxisome, and mitochondrion. Alternative splicing results in multiple transcript variants encoding distinct isoforms. Additional transcript variants have been described but have not been experimentally verified.[provided by RefSeq, Sep 2009]
Entrez Gene ID
3416
UniProt ID
P14735
Alternative Names
Insulin Degrading Enzyme
Function
Plays a role in the cellular breakdown of insulin, APP peptides, IAPP peptides, natriuretic peptides, glucagon, bradykinin, kallidin, and other peptides, and thereby plays a role in intercellular peptide signaling (PubMed:2293021, PubMed:10684867, PubMed:26968463, PubMed:17051221, PubMed:17613531, PubMed:18986166, PubMed:19321446, PubMed:23922390, PubMed:24847884, PubMed:26394692, PubMed:29596046, PubMed:21098034).

Substrate binding induces important conformation changes, making it possible to bind and degrade larger substrates, such as insulin (PubMed:23922390, PubMed:26394692, PubMed:29596046).

Contributes to the regulation of peptide hormone signaling cascades and regulation of blood glucose homeostasis via its role in the degradation of insulin, glucagon and IAPP (By similarity).

Plays a role in the degradation and clearance of APP-derived amyloidogenic peptides that are secreted by neurons and microglia (PubMed:9830016, PubMed:26394692) (Probable).

Degrades the natriuretic peptides ANP, BNP and CNP, inactivating their ability to raise intracellular cGMP (PubMed:21098034).

Also degrades an aberrant frameshifted 40-residue form of NPPA (fsNPPA) which is associated with familial atrial fibrillation in heterozygous patients (PubMed:21098034).

Involved in antigen processing. Produces both the N terminus and the C terminus of MAGEA3-derived antigenic peptide (EVDPIGHLY) that is presented to cytotoxic T lymphocytes by MHC class I.

(Microbial infection) The membrane-associated isoform acts as an entry receptor for varicella-zoster virus (VZV).
Biological Process
Amyloid-beta clearance Source: ARUK-UCL
Amyloid-beta clearance by cellular catabolic process Source: ARUK-UCL
Amyloid-beta metabolic process Source: UniProtKB
Antigen processing and presentation of endogenous peptide antigen via MHC class I Source: UniProtKB
Bradykinin catabolic process Source: UniProtKB
Cellular protein catabolic process Source: UniProtKB
Determination of adult lifespan Source: UniProtKB
Hormone catabolic process Source: UniProtKB
Insulin catabolic process Source: UniProtKB
Insulin metabolic process Source: UniProtKB
Insulin receptor signaling pathway Source: UniProtKB
Peptide catabolic process Source: UniProtKB
Positive regulation of protein binding Source: UniProtKB
Positive regulation of protein catabolic process Source: ARUK-UCL
Protein catabolic process Source: ARUK-UCL
Proteolysis Source: UniProtKB
Proteolysis involved in cellular protein catabolic process Source: UniProtKB
Regulation of aerobic respiration Source: ARUK-UCL
Ubiquitin recycling Source: UniProtKB
Cellular Location
Cytosol; Secreted; Cell membrane. Present at the cell surface of neuron cells. The membrane-associated isoform is approximately 5 kDa larger than the known cytosolic isoform.
PTM
The N-terminus is blocked.

Azam, M. S., Wahiduzzaman, M., Reyad-ul-Ferdous, M., Islam, M. N., & Roy, M. (2022). Inhibition of insulin degrading enzyme to control diabetes mellitus and its applications on some other chronic disease: A critical review. Pharmaceutical research, 39(4), 611-629.

González-Casimiro, C. M., Merino, B., Casanueva-Álvarez, E., Postigo-Casado, T., Cámara-Torres, P., Fernández-Díaz, C. M., ... & Perdomo, G. (2021). Modulation of insulin sensitivity by insulin-degrading enzyme. Biomedicines, 9(1), 86.

Leissring, M. A., González-Casimiro, C. M., Merino, B., Suire, C. N., & Perdomo, G. (2021). Targeting insulin-degrading enzyme in insulin clearance. International Journal of Molecular Sciences, 22(5), 2235.

Leissring, M. A. (2021). Insulin-degrading enzyme: Paradoxes and possibilities. Cells, 10(9), 2445.

Sousa, L., Guarda, M., Meneses, M. J., Macedo, M. P., & Vicente Miranda, H. (2021). Insulin‐degrading enzyme: an ally against metabolic and neurodegenerative diseases. The Journal of pathology, 255(4), 346-361.

Maianti, J. P., Tan, G. A., Vetere, A., Welsh, A. J., Wagner, B. K., Seeliger, M. A., & Liu, D. R. (2019). Substrate-selective inhibitors that reprogram the activity of insulin-degrading enzyme. Nature chemical biology, 15(6), 565-574.

Kurochkin, I. V., Guarnera, E., & Berezovsky, I. N. (2018). Insulin-degrading enzyme in the fight against Alzheimer’s disease. Trends in pharmacological sciences, 39(1), 49-58.

Zhang, Z., Liang, W. G., Bailey, L. J., Tan, Y. Z., Wei, H., Wang, A., ... & Tang, W. J. (2018). Ensemble cryoEM elucidates the mechanism of insulin capture and degradation by human insulin degrading enzyme. Elife, 7, e33572.

Li, H., Wu, J., Zhu, L., Sha, L., Yang, S., Wei, J., ... & Yang, Z. (2018). Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer’s disease: possible mechanisms of IDE in T2D and AD. Bioscience reports, 38(1), BSR20170862.

Villa-Pérez, P., Merino, B., Fernández-Díaz, C. M., Cidad, P., Lobatón, C. D., Moreno, A., ... & Perdomo, G. (2018). Liver-specific ablation of insulin-degrading enzyme causes hepatic insulin resistance and glucose intolerance, without affecting insulin clearance in mice. Metabolism, 88, 1-11.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-IDE Recombinant Antibody (A372)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare